Cinctive Capital Management LP Makes New $2.08 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cinctive Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 273,959 shares of the biotechnology company’s stock, valued at approximately $2,082,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BCRX. CWM LLC increased its holdings in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its position in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $63,000. Finally, DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth about $74,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.38 on Tuesday. The company has a fifty day moving average of $7.59 and a two-hundred day moving average of $7.32. The company has a market capitalization of $1.53 billion, a PE ratio of -12.10 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period last year, the company earned ($0.19) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.